Text Size
Santen Global

2024 IR News

RSS

IR News

Santen Announces Completion of Share Buyback
Santen New Drug Application Filing Accepted for Review in South Korea and Vietnam for the Use of STN1013001 (Cationic Emulsion of Latanoprost 50μg/mL) in Glaucoma
Santen Announces Status of Share Buyback
【Updated】Corporate Governance Report
Santen and Arctic Vision execute a commercial collaboration agreement for ARVN001, a suprachoroidal space injection therapy for the treatment of uveitic macular edema
Santen Announces Share Buyback
Santen Announces Cancellation of Treasury Shares
Santen Announces Completion of Share Buyback
Santen Reports the 2nd Quarter Fiscal 2024 Consolidated Performance
Santen launches Rhopressa® ophthalmic solution 0.02% (netarsudil mesylate), in South Korea, for the treatment of patients with open-angle glaucoma or ocular hypertension
Santen Announces Status of Share Buyback
Santen Announces Corporate Volunteer Partnership with Be My Eyes
Santen Announces Status of Share Buyback
Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
Santen applies for manufacturing and marketing approval in Japan for STN1012600 ophthalmic solution (sepetaprost ophthalmic solution), a treatment for glaucoma and ocular hypertension with a novel mechanism of action for lowering intraocular pressure
Santen Publishes its Annual Integrated Report “Santen Report 2024”
Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
Santen Announces Status of Share Buyback
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium
Santen Reports the 1st Quarter Fiscal 2024 Consolidated Performance
Santen Announces Status of Share Buyback
Corporate Governance Report
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Corporate Governance Report
Santen Announces Status of Share Buyback
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Notice of Corporate Officer Change
Santen Announces Status of Share Buyback
Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis, goes on sale in Japan
Notice of Board of Director and Corporate Auditor Nominations
Notice of Recording of Impairment Loss and Loss on Valuation of Financial Assets
Santen Announces Share Buyback
Santen Reports Fiscal 2023 Consolidated Performance
Santen and Mitsubishi Tanabe Pharma announce the conclusion of a contract for the joint sales promotion in Japan of Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis
Santen and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL
Santen Positioned for Further Growth in China Following Completion of Santen Vision Park
Santen obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis
Santen Announces Change of Representative Director of the Board
Santen Announces Cancellation of Treasury Shares
Santen Announces Completion of Share Buyback
Notice of Corporate Officer Changes
Santen Announces Status of Share Buyback
Eyedrops for slowing the progression of myopia: Santen files application for manufacturing and marketing approval STN1012700 / DE-127 (atropine sulfate hydrate ophthalmic solution) in Japan
Revision of Dividend Forecast
Santen Reports the 3rd Quarter Fiscal 2023 Consolidated Performance
Santen Announces Status of Share Buyback
Japan Approval Obtained for Ophthalmic VEGF inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL
Santen Announces Status of Share Buyback
 
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved